DC CHEMICALS · LITERATURE EVIDENCE
XH-07: Formulation & Performance
Evidence from Wang et al., Scientific Reports (2024)
Product and study identity
| Item | Evidence-based interpretation | Source |
|---|---|---|
| XH-07 | Ionizable cationic carrier lipid; the supporting information labels its structure “XH-07 (Lipid #4 in patent)”. | Supplementary Table 1 |
| JCXH-211 | Complete RNA–LNP formulation. This is the experimental intervention to which the biological results below apply. | Main article, Results |
| Research context | Preclinical IL-12 RNA delivery and tumor immunotherapy. This paper does not establish a T-cell engager or CAR-T application. | Main article |
Published findings relate to the complete JCXH-211 experimental formulation. They are not guaranteed performance specifications for DC67983.
Formulation overview
The study identifies the following four lipid components. This overview records component identities and the reported particle characteristics; it is not a preparation protocol.
| Component | Role | DC Chemicals product |
|---|---|---|
| XH-07 | Ionizable carrier lipid | DC67983 · XH-07 |
| Cholesterol | Structural lipid | DCD-041 · Cholesterol |
| DSPC | Helper phospholipid | DC57005 · DSPC |
| DMG-PEG2000 | PEG lipid | DC40169 · DMG-PEG2000 |
Source: main article, Methods. Component links point to the DC Chemicals catalog; they do not identify the supplier or material lot used by the authors.
| Reported attribute | Result | Interpretation / source |
|---|---|---|
| Mean particle diameter | Approximately 80 nm | Complete formulated particles, not a specification of neat XH-07. Main article, Methods; Supplementary Fig. 1. |
| Polydispersity index | 0.07–0.16 | Reported formulation characterization range; not a guaranteed lot-release range for the supplied lipid. Main article, Methods. |
| RNA encapsulation | Above 85% | Reported for the complete formulation. Main article, Methods. |
| Zeta potential | Distribution shown in Supplementary Fig. 1B | The previous catalog value is not used as a universal or independently verified specification. |
Cellular and animal performance
Results are grouped by endpoint and model to keep particle distribution, expression, antitumor activity and tolerability separate.
| Study context | Reported result | Meaning and limits | Source |
|---|---|---|---|
| Cultured tumor cells and primary normal cells | B16F10, MC38 and EMT6 cells showed IL-12 expression; the tested primary normal cells showed little or no detectable expression. | An expression readout in the tested cell panel. It does not independently quantify lipid uptake or establish universal tumor specificity. | Fig. 4B |
| Distribution versus expression | Early labeled-particle distribution was predominantly hepatic, while RNA and protein expression persisted longer in tumor tissue. | Lipid-particle distribution, RNA abundance and protein expression are different endpoints. Persistent tumor expression should not be relabeled as selective tumor accumulation of XH-07. | Figs. 2–4; Discussion |
| B16F10 melanoma: immune profiling | JCXH-211 alone reduced tumor-infiltrating PMN-MDSCs; total T-cell and NK-cell infiltration did not significantly increase in the monotherapy comparison. | The negative infiltration finding is retained. Combination treatment with anti-PD1 showed increased T-cell and NK-cell infiltration in a separate comparison. | Fig. 5 |
| B16F10 melanoma: complete response | Combination with anti-PD1: 50%; JCXH-211 monotherapy: 12.5% in the illustrated study cohorts. | Complete response is distinct from survival. These are formulation-level results from a particular mouse experiment, not an isolated-lipid efficacy claim. | Fig. 6 and accompanying Results; n=8 per group |
| EMT6 mammary tumor: selected treatment comparison | Complete responses were observed in 6/8 mice with monotherapy and 7/8 with combination treatment in the selected comparison. | The highest-treatment-level combination did not significantly improve tumor-growth inhibition over monotherapy. These values do not represent every experimental group. | Fig. 7E, I; Results |
| EMT6 tumor rechallenge | 17/21 previously complete-responding mice resisted rechallenge. | This is a selected responder cohort, not the response rate of all initially treated animals. | Fig. 7J |
| Cynomolgus monkey exploratory tolerability | Two animals, one male and one female, were evaluated. The authors reported no noticeable systemic toxicity under the study conditions; the male showed transient inflammatory-marker changes. | A very small exploratory study cannot establish comprehensive safety, chronic tolerability or a human therapeutic window. | Supplementary Tables 2–3; main article |
What the study supports
XH-07 is a literature-linked carrier-lipid reference for preclinical IL-12 RNA tumor-immunotherapy research. The paper provides formulation-level biological evidence, including both positive and null findings. It does not provide a matched demonstration that XH-07 outperforms SM-102 or ALC-0315, and it does not establish a general-purpose tumor-targeting property of the isolated lipid.
Original figures and supporting evidence
Consult the original publication for the complete figures, legends and statistical annotations.
- Fig. 4B: cellular expression comparison.
- Fig. 5: immune-cell profiling, including nonsignificant findings.
- Figs. 6–7: tumor response and survival endpoints.
- Supplementary Fig. 1: particle characterization; Tables 2–3: exploratory primate observations.
Reference
Wang Z, Chen Y, Wu H, et al. Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses. Scientific Reports 14, 7366 (2024). doi:10.1038/s41598-024-57997-w. Main article and accompanying Supplementary Material reviewed.
Evidence review: 26 October 2026. This page is a study summary, not an experimental protocol.